TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10891736
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg with 2 g of amoxicillin and 1 g of clarithromycin for 10 days
Study: 10891736
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg with 2 g of amoxicillin and 1 g of clarithromycin for 7 days
Study: 8922877
Drug: ZK 136295
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 136295 (60 micrograms i.v. and 120/240 micrograms oral)
Study: 8922877
Drug: ZK 115194
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 115194 (60 micrograms i.v. and 240 micrograms oral)
Study: 8922877
Drug: Ethinylestradiol (EE2)
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinylestradiol (EE2) (60 micrograms i.v. and 120/240 micrograms oral)
Study: 1348771
Drug: Handrub with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handrub with 2 portions of 3 ml of 2-propanol 60% v/v for 1 min
Study: 29696420
Drug: Dexamethasone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (3 daily 8-mg doses starting 48 hours before bleaching)
Study: 29696420
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 daily doses starting 48 hours before bleaching)
Study: 26673440
Drug: Guideline-oriented medical
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-oriented medical treatment
Study: 26673440
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (carotid endarterectomy or carotid artery stenting)
Study: 24850625
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg/d of zinc sulfate, 10 mg/d of iron, and 0.5 mg/d of copper)
Study: 24850625
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 mg/d of iron and 0.5 mg/d of copper)
Study: 21961763
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy for Command Hallucinations + Treatment as Usual
Study: 17688659
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg twice daily for 12 weeks
Study: 7772354
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl patch (75 micrograms/hr) for 72 hours
Study: 6771814
Drug: Cloxazolam as
Normalized name: cloxazolam
DrugBank: Cloxazolam (DB01553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxazolam as a tranquilizer
Study: 6771814
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no tranquilizer)
Study: 31876397
Drug: Combined Individual
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Individual and Family Cognitive Behavioural Therapy (IFCBT)
Study: 31422012
Drug: Contemporary drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contemporary drug-eluting stents (DES)
Study: 22878432
Drug: Sativex (oromucosal),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sativex (oromucosal), self-titrated to symptom relief or maximum tolerated dose (maximum of 130 mg THC and 120 mg CBD daily)
Study: 20634174
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate 500 mcg daily
Study: 20634174
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate 1000 mcg daily
Study: 19769830
Drug: Acetaminophen/codeine 600/60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/codeine 600/60 mg
Study: 2955899
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg BID for four months
Study: 2955899
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg BID for four months
Study: 24036849
Drug: Endurance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance training on a cycle-ergometer or aquatic-bike, 30 min daily at 60% of VO2peak for 3 weeks
Study: 21502634
Drug: Danoprevir monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir monotherapy
Study: 18032491
Drug: CD8(+) T-cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD8(+) T-cell peptide epitope vaccine
Study: 9278196
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of felbamate (600 mg or 1200 mg)
Study: 9278196
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of felbamate (600 mg or 1200 mg every 12 h)
Study: 8350886
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g daily for one year)
Study: 25039961
Drug: Parent-mediated communication-focused
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-mediated communication-focused treatment
Study: 21220402
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of ≥ 6 μg/day of bromodichloromethane
Study: 11474387
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg; 2 doses) with NAP
Study: 11474387
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg; 1 dose) with PEG-EL
Study: 9605803
Drug: Three full
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three full doses of PRP-T or PRP-CRM197
Study: 9605803
Drug: Fractional-dose regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional-dose regimens (one half or one third of the full dose)
Study: 9605803
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of PRP-T
Study: 9605803
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of PRP-CRM197
Study: 8581408
Drug: BT 563
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT 563 (10 mg/day for 12 days)
Study: 8581408
Drug: Cyclosporin (CyA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (CyA) and low dose steroids
Study: 340129
Drug: Intra-articular methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular methotrexate (5 mg, two injections of 2.5 mg a week apart)
Study: 340129
Drug: Intra-articular triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular triamcinolone hexacetonide (20 mg, single injection)
Study: 31350798
Drug: Topical autologously
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical autologously sourced PRP added to a preservative cosmetic base applied twice daily for 8 weeks
Study: 31350798
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control serum applied twice daily for 8 weeks
Study: 27624149
Drug: D1 receptor
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 receptor antagonist fluphenazine (FLU; 3 mg)
Study: 27624149
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor antagonist haloperidol (HAL; 3 mg)
Study: 26051201
Drug: 12-month adherence
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month adherence program and statin medication
Study: 26051201
Drug: Statin medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin medication only
Study: 21943331
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (SG)
Study: 19136486
Drug: ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months
Study: 15508522
Drug: Dummy dentition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy dentition with simulated cavity preparation by 5 operators.
Study: 9517642
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg t.i.d. for 2 weeks
Study: 3191940
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg at 6 p.m. (Fam 6)
Study: 3191940
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg at 10 p.m. (Fam 10)
Study: 23247974
Drug: Transoral robotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transoral robotic surgery with adjuvant therapy
Study: 21200077
Drug: Inhaled loxapine
Normalized name: loxapine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled loxapine (5 mg)
Study: 15583115
Drug: Metyrapone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (1 g/d)
Study: 11583752
Drug: Normal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal treatment and follow-up (control group)
Study: 2897197
Drug: Tazifylline 5
Normalized name: bamifylline
DrugBank: Bamifylline (DB13203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazifylline 5 mg
Study: 2897197
Drug: Tazifylline 10
Normalized name: bamifylline
DrugBank: Bamifylline (DB13203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazifylline 10 mg
Study: 2897197
Drug: Tazifylline 15
Normalized name: bamifylline
DrugBank: Bamifylline (DB13203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazifylline 15 mg
Study: 31392822
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg dulaglutide
Study: 31392822
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg dulaglutide
Study: 25568568
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 µg/kg IV bolus) + Nitroglycerin (400 µg/spray, 2 puffs)
Study: 25568568
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 µg/kg IV bolus)
Study: 7509329
Drug: 5‐FU (5‐fluorouracil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU (5‐fluorouracil) concurrent with either 50‐52 Gy in 20‐21 or 30‐36 Gy in 10‐15 fractions (radical)
Study: 7509329
Drug: 5‐FU (5‐fluorouracil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU (5‐fluorouracil) concurrent with either 50‐52 Gy in 20‐21 or 30‐36 Gy in 10‐15 fractions (palliative)
Study: 25572008
Drug: nab-paclitaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (100 mg/m2 weekly) plus carboplatin (C)
Study: 25572008
Drug: solvent-based paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: solvent-based paclitaxel (200 mg/m2 every 3 weeks) plus carboplatin (C)
Study: 21311897
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL at peak stress (40 μg/kg/min of dobutamine)
Study: 21471262
Drug: Levosimendan infusion
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan infusion
Study: 10180369
Drug: Cheaper treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cheaper treatment
Study: 10180369
Drug: More expensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More expensive treatment
Study: 22388601
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG) - Pharmacist involvement in drug therapy management, including targeted drug counselling before discharge.
Study: 18714239
Drug: Serial CE
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial CE (concurrent exercise)
Study: 18714239
Drug: Integrated CE
Normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated CE (concurrent exercise)
Study: 12515747
Drug: Intravenous levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous levosimendan (Levo)
Study: 11269973
Drug: Antineutrophil cytoplasmic
Normalized name: c-Antineutrophil cytoplasmic antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antineutrophil cytoplasmic antibodies (ANCAs) in IBD patients
Study: 8936353
Drug: Sinemet CR
Normalized name: Sinemet CR
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sinemet CR (50/200 mg carbidopa/mg levodopa)
Study: 8936353
Drug: Sinemet STD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet STD (25/100 mg)
Study: 1587068
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg alprazolam
Study: 19378514
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of remifentanil (RG)
Study: 19378514
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of sufentanil (SG)
Study: 11165726
Drug: β-blocker therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker therapy in pregnancy (meta-analysis of trials)
Study: 11165726
Drug: β-blocker therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker therapy in pregnancy (prospective cohort)
Study: 9840605
Drug: Intravenous ARTS
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ARTS (120 mg)
Study: 9840605
Drug: Oral ARTS
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ARTS (100 mg)
Study: 2826285
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial embolization once + monthly chemotherapy with high doses of 5‐fluorouracil
Study: 2826285
Drug: Monthly chemotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly chemotherapy with high doses of 5‐fluorouracil
Study: 2024656
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate (initial dose 8.11 mmol (325 mg Ca2+) per meal, adjusted to 14.6 mmol (586 mg) Ca2+ per meal)
Study: 319141
Drug: Methylprednisolone (steroids)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (steroids)
Study: 31416212
Drug: Cardiose® (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiose® (500 mg of 2S‐Hesperidin)
Study: 25602164
Drug: HMLE capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMLE capsules
Study: 24851570
Drug: Oatmeal (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oatmeal (70 g daily, 3 g beta-glucan)
Study: 24851570
Drug: Rice porridge
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice porridge (control product, 70 g daily)
Study: 20847731
Drug: Ice cream
Normalized name: Nice Cream 2% Topical Dental Foam (mint)
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice cream intake/kg
Study: 20847731
Drug: Pre-ice cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-ice cream fullness
Study: 15860518
Drug: G‐CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (5 microg/kg/day s.c. for 4 consecutive days)
Study: 9337376
Drug: Quadrivalent rotavirus
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent rotavirus vaccine (4x10^5 plaque-forming units per dose)
Study: 2954736
Drug: Isradipine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (15 mg/day)
Study: 31490268
Drug: Dabigatran (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (110 mg bid)
Study: 26109251
Drug: Dabigatran (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (150 mg bid)
Study: 28339794
Drug: Warfarin (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (with heparin bridging)
Study: 28339794
Drug: Warfarin (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (without heparin bridging)
Study: 21443837
Drug: Anticoagulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation with 40 mg of enoxaparin subcutaneously once daily for 21 days
Study: 18493597
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPTi) using sulfadoxine-pyrimethamine (SP)
Study: 12679453
Drug: Continue GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue GH therapy (0.35 IU/kg x wk)
Study: 12679453
Drug: Discontinue GH
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue GH therapy
Study: 12679453
Drug: Continue GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue GH therapy
Study: 31597555
Drug: Telephone-based self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based self-help cognitive behavioural therapy (tel-CBT)
Study: 29044032
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels higher than 50 nmol/L
Study: 29044032
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (lower than 37.5 nmol/L)
Study: 23597811
Drug: Pre-sliced fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-sliced fruit (apples) served in treatment schools
Study: 21678741
Drug: DTaP-IPV//PRP T
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV//PRP T vaccine (Pentaxim)
Study: 10970701
Drug: Early vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early vaccination with several doses of Hib vaccine starting at three months
Study: 10970701
Drug: Late vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late vaccination with a single dose of Hib vaccine at two years
Study: 8874564
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (80 micrograms.kg-1.min-1)
Study: 1394219
Drug: Exemestane (FCE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (FCE 24304) 25 mg
Study: 1394219
Drug: Exemestane (FCE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (FCE 24304) 50 mg
Study: 1394219
Drug: Exemestane (FCE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (FCE 24304) 200 mg
Study: 1394219
Drug: Exemestane (FCE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (FCE 24304) 400 mg
Study: 1394219
Drug: Exemestane (FCE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (FCE 24304) 800 mg
Study: 1394219
Drug: Exemestane (FCE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (FCE 24304) (all doses)
Study: 3903778
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg naproxen
Study: 31870413
Drug: Immediate prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate prescription for antibiotics
Study: 31870413
Drug: Immediate prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate prescription for antibiotics plus a 7-day course of cranberry capsules
Study: 31870413
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules plus a delayed prescription for antibiotics
Study: 24937967
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone gel supplementation (study group, n = 71)
Study: 24937967
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug for luteal support (control group, n = 78)
Study: 22320449
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with almotriptan
Study: 22320449
Drug: Non-early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-early treatment
Study: 17950147
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose complex, 200 mg weekly for 5 weeks
Study: 16253504
Drug: Dydrogesterone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone (10 mg b.i.d.)
Study: 16253504
Drug: Intramuscular human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular human chorionic gonadotrophin (hCG; 5000 IU every 4 days)
Study: 16253504
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (controls)
Study: 9988780
Drug: MCT oil
Normalized name: Organic MCT Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT oil (71 g)
Study: 9988780
Drug: Canola oil
Normalized name: Canola Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canola oil (71 g)
Study: 1765893
Drug: Behaviorally based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviorally based smoking-cessation program with methadone dose increase
Study: 28103159
Drug: Medication (methylphenidate)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (methylphenidate)